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eur objective in this paper is to address the most important
dvances in the last year as they pertain directly to the
therothrombotic process, including those in epidemiology
nd public health, mechanisms of disease, prevention, early
etection and risk stratification, and treatment.
pidemiology and Public Health Impact
he trends in risk factor control in industrialized regions
etween 1998 and 2006 were evaluated in more than
00,000 patients from the U.S. and 4 European countries.
lthough there were modest improvements, large propor-
ions of patients remained undertreated, particularly those
ith the highest risk (1). This included subjects with
xtracardiac atherosclerosis, as highlighted in a series of
atients with peripheral arterial disease who experienced
orse long-term outcomes and received fewer secondary
revention therapies than matched patients with coronary
eart disease (CHD) (2). Addressing potential sex differ-
nces in risk, the INTERHEART study suggested that the
ame 9 modifiable factors are associated with myocardial
nfarction (MI) both in men and women worldwide, and
hat the younger age at presentation in men may be largely
elated to different risk factor exposure (3). Data from the
.S. indicated that progress in hypertension control has
een largely restricted to men; uncontrolled hypertension
as become more prevalent in women, particularly at older
ges (Fig. 1) (4). Moreover, the Global Burden of Disease
000 study showed that approximately one-half of the
urden of stroke and CHD worldwide is attributable to
ypertension or pre-hypertension and that 80% occurs in
ow- and middle-income countries (5).
Better risk factor control has translated into global
ecreases in age-adjusted mortality for CHD. However,
ata from the U.S. caused concern by showing a paradoxical
eveling or even an increase in mortality for 35- to 44-year-
ld individuals, probably reflecting worsened risk profiles in
he young (6). A collective analysis of 3 prospective cohorts
rom different countries confirmed that dyslipidemia in
hildren predicts abnormal lipid concentrations in adult-
ood (7). Analogous findings regarding the association
rom the Zena and Michael A. Wiener Cardiovascular Institute/Marie-Josee and
enry R. Kravis Center for Cardiovascular Health, Mount Sinai School of Medicine,t
ew York, New York.
Manuscript received November 17, 2008, accepted December 18, 2008.etween elevated childhood blood pressure and hyperten-
ion later in life were reported in a meta-analysis of 50
ohort studies (8). Similarly, childhood body mass index
BMI) (Fig. 2) proved to be a predictor of later CHD (9).
ecent data from the National Health and Nutrition
xamination Survey showed no significant changes in the
revalence of high BMI in U.S. children and adolescents
etween 1999 and 2006 (10). However, a study from
inland indicated that type 1 diabetes mellitus in children
as doubled over the past 25 years, a change intimately
elated to obesity (11).
echanisms of Disease
educed shear stress, which occurs preferentially at vessel
ifurcations, is known to favor plaque formation. An eval-
ation of extracellular matrix structure using 2-photon
xcitation microscopy revealed a nearly confluent elastin
urface layer along the vessel wall except at branching
oints, where dense collagen-proteoglycan complexes were
xposed, contributing to low-density lipoprotein (LDL)
holesterol retention (12). In another experimental study
hat performed serial coronary intravascular ultrasound
IVUS) and histopathologic analysis, it was shown that low
hear stress is also associated with development of high-risk
laque features such as inflammation, thin fibrous cap,
uptured internal elastic lamina, or eccentric remodeling
13). Conversely, localized high shear stress was identified
n regions of plaque rupture in patients with acute coronary
yndromes (Fig. 3) (14). Demonstration of increased osteo-
alcin expression by endothelial progenitor cells in patients
ith CHD suggested a role for these cells in human vascular
alcification (15). Also, an elegant study in apolipoprotein
-deficient mice provided direct quantitative evidence of
he role of bone marrow-derived endothelial progenitor cells
n the endothelial repair of atherosclerotic lesions with a
igh cellular turnover (16).
Plaque neovascularization is a marker of vulnerability, but its
eterminants are incompletely understood. A study in human
arotid specimens demonstrated the presence of intraplaque
ypoxia that, in turn, correlated with neovessel density and
nhanced expression of hypoxia-inducible factor, a mediator
hat stimulates, among other things, the synthesis of vascular
ndothelial growth factor (17). In addition, a potential role of
issue factor-containing microparticles released from apoptotic
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April 14, 2009:1326–37 Year in Atherothrombosisacrophages as a stimulus for neovascularization was also
escribed (18). Immature neovascularization favors in-
raplaque hemorrhage and the release of hemoglobin-bound
ron that contributes to plaque growth and destabilization.
omozygosis for the haptoglobin 2 gene was shown to
ause impaired clearance of hemoglobin, as demonstrated by
ncreased plaque iron accumulation, which may explain the
Figure 1 Trends in Hypertension Control in Older American Adu
Age-standardized prevalence (in percentage) of uncontrolled hypertension for 60
1988 to 1992 and 2001 to 2003. Hypertension control has decreased in women
Figure 2 Obesity in Children and Risk of Future Disease
Association between childhood body mass index (BMI) and the risk of coronary he
hazard ratios and 95% confidence intervals for a 1-U increase in BMI z score (the
divided by the standard deviation of the reference population). Note that risk is higherigher risk associated with this genotype, particularly in
atients with diabetes (19).
arly Detection and Risk Stratification
onventional risk factors. Data from the INTERHEART
tudy further characterized the relationship between dyslipide-
ld men and women in the U.S. in 2 different time periods:
e studied period. Reprinted, with permission, from Ezzati et al. (4).
ease in adulthood for boys (A) and girls (B). Increased risks are expressed as
is calculated as the difference between every child’s BMI and the reference BMI,
child’s age increases. Reprinted, with permission, from Baker et al. (9).lts
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Year in Atherothrombosis April 14, 2009:1326–37ia and likelihood of a first MI, and proposed the nonfasting
polipoprotein B/A1 ratio as the best lipid-based predictor
egardless of age, sex, or ethnic group (20). These findings were
onfirmed in a post hoc analysis of 2 large statin trials in
atients with established CHD (21). Similarly, the ratio of
otal to high-density lipoprotein (HDL) cholesterol had a
etter discriminative power than individual total, LDL, HDL,
r non-HDL cholesterol measures for the prediction of fatal
HD in a meta-analysis of 61 prospective observational
tudies including almost 900,000 apparently healthy adults.
nterestingly, lipid parameters were not associated with mor-
ality secondary to stroke (22). The inverse relationship be-
ween HDL cholesterol and coronary risk, confirmed in the
ame meta-analysis, persisted even for markedly reduced LDL
holesterol (60 mg/dl) in a separate publication (23).
That outcomes are impaired to a similar degree in
ndividuals with diabetes requiring glucose-lowering
herapy as in patients without diabetes with a previous
I was confirmed in a population study that followed
ore than 3 million individuals for 5 years (24). More-
ver, a Finnish investigation demonstrated that the
rends for reduced CHD incidence and mortality noted
n past decades are largely restricted to nondiabetic
ndividuals (25). Regarding other metabolic abnormali-
ies, a combined analysis of 2 large prospective trials in
lderly individuals suggested that the presence of the
etabolic syndrome may be a better predictor of incident
iabetes than of cardiovascular disease (26).
Obesity was one of the risk factors that received closer
ttention in 2008. Long-term (approximately 24 years)
Figure 3 In Vivo Quantification of Coronary Shear Stress
(A) Longitudinal and cross-sectional images from a 3-dimensional coronary
intravascular ultrasound, demonstrating a ruptured plaque (yellow asterisk) in
a patient with unstable angina. (B) Corresponding color map of in vivo shear
stress distribution, derived through computational fluid dynamics analysis. An
area of localized high shear stress (red circle) is noted at the level of the rup-
ture. Reprinted, with permission, from Fukumoto et al. (14).ollow-up of the Framingham Offspring study unveiled an tndependent association between BMI and risk of a first
ardiovascular event, even after adjustment for other factors
ommonly accompanying obesity such as hypertension,
iabetes, or dyslipidemia (27). Obesity was also shown to
trengthen the association between hypertension and car-
iovascular risk in a cohort of more than 1,000,000 men
28). Moreover, waist circumference and waist-to-hip ratio
ere independently related to the presence of abdominal
ortic aneurysms in men (29).
Many common scores for cardiovascular risk stratification
stimate the likelihood of developing CHD or a fatal
therosclerotic event. In 2008, novel algorithms were pro-
osed to predict fatal and nonfatal events, including stroke,
eripheral arterial disease, or heart failure. These models are
ased on age, sex, systolic blood pressure, treatment for
ypertension, smoking, diabetes, and lipid measures such as
otal and/or HDL cholesterol (30,31). Importantly, algo-
ithms that do not require laboratory-based tests, and in
hich cholesterol quantification is replaced by the BMI,
ere simultaneously developed (30,31). Such simplified,
ffordable approaches may be particularly useful in resource-
oor regions.
nkle-brachial index (ABI) and biomarkers. A meta-
nalysis of 16 prospective studies including more than
8,000 individuals provided justification for routine quan-
ification of the ABI in clinical practice (Fig. 4). In
omparison with the normal value (1.1 to 1.4), a low ABI
0.90) doubled or tripled cardiovascular risk after adjusting
or the Framingham risk score. Furthermore, inclusion of
he ABI in stratification resulted in substantial reclassifica-
ion of risk category (32).
Increased circulating oxidized LDL levels were associated
ith future metabolic syndrome after multivariate adjust-
ent in individuals between ages 18 and 30 years followed
rospectively for 20 years (33). Conversely, high concentra-
ions of interleukin-5 correlated with reduced carotid
ntima-media thickness (CIMT), probably through the
nduction of antibodies against oxidized LDL (34). In
ontrast to previous series, a large prospective study in more
han 11,000 men pointed toward an independent contribu-
ion of low testosterone levels to cardiovascular mortality
35). Reinforcing the link between kidney disease and
therothrombosis, a substudy in patients with stable CHD
nd preserved systolic function demonstrated that albumin-
ria (even below the threshold of abnormality) predicted
ll-cause and cardiovascular mortality after accounting for
ther risk factors and glomerular filtration rate (36). Detec-
ion of subclinical myocardial damage was addressed in
nother investigation in the elderly that quantified plasma
roponin I with a high-sensitivity assay, the CIMT and
ardiac function with ultrasound and myocardial scar with
agnetic resonance imaging (MRI). In multivariate analy-
is, only male sex, ischemic electrocardiographic changes,
nd elevated N-terminal pro-brain natriuretic peptide levels,
ut not myocardial scarring, were associated with increased
roponin T concentrations (37).
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April 14, 2009:1326–37 Year in AtherothrombosisSeveral reports addressed the use of serum markers
pecifically in noncardiac atherothrombosis. In patients with
schemic stroke, elevated levels of prothrombin fragment F
.2 (an indicator of thrombin generation) were associated
ot only with large aortic plaques on transesophageal
chocardiography but also with recurrent events, suggesting
potential contribution of a hypercoagulable state to the
evelopment of stroke in the presence of severe aortic
therosclerosis (38). Similarly, systemic inflammation, as
videnced by high levels of C-reactive protein (CRP), serum
myloid A, and interleukin-6, may play an important role in
he pathogenesis of stroke after an acute coronary syndrome
39). In patients with peripheral arterial disease, increased
oncentrations of CRP, serum amyloid A, and D-dimer
redicted decreased survival during the first 2 years after
uantification (40).
Regarding risk stratification algorithms, a Reynolds Risk
core that includes plasma concentrations of CRP (and
arental history of MI) was proposed for risk stratification
n men as previously described in women (41). Additionally,
study in 1,135 elderly men with and without cardiovas-
ular disease described incremental prognostic value for the
uantification of CRP, N-terminal pro-brain natriuretic
eptide, troponin I, and cystatin C combined. The risk of
ardiovascular mortality in patients with elevated concen-
rations of 2, 3, or 4 biomarkers was increased by a factor of
, 7, and 17, respectively (42).
enetics. The role of recent genome-wide association
tudies in understanding the contribution of genetic variants
o atherothrombosis, diabetes, or dyslipidemias was ele-
antly reviewed elsewhere (43). Several investigations eval-
ated the significance of genetic polymorphisms associated
ith risk factors and their influence on event rates. In a
ohort of patients mostly free of cardiovascular disease, a
Figure 4 Ankle-Brachial Index and Mortality
Unadjusted hazard ratios for total mortality for both men and women as a
function of the ankle-brachial index. Reprinted, with permission, from Fowkes et alenotype score based on the number of alleles associated with higher LDL or lower HDL cholesterol at 9 genetic loci
ndependently predicted incident events, even after adjust-
ent for other covariates, including baseline lipid levels
44). Polymorphisms of the paraoxonase-1 gene, an enzyme
hat influences the antioxidant and anti-inflammatory ac-
ions of HDL, were also independent predictors in multi-
djusted models that controlled for HDL levels or statin use
45). In contrast, loss-of-function mutations of the adeno-
ine triphosphate-binding cassette transporter A1, involved
n HDL-mediated reverse cholesterol transport, were not
ssociated with increased CHD in 3 large studies (46).
ombined data from 4 large independent studies showed
hat 4 specific mutations of the CRP gene do not portend
ncreased cardiovascular risk despite being associated with
igher plasma CRP concentrations (47).
nvasive imaging. In the field of IVUS, the influence of
iabetes on coronary atherosclerosis was revisited in a
ooled analysis of 5 trials that concluded that diabetes is
ndependently associated with higher atheroma burden,
aster plaque progression, and possibly inadequate remod-
ling (48). A virtual histology 3-vessel IVUS evaluation of
atients with unstable and stable CHD demonstrated a
igher frequency of thin-cap fibroatheromata in the former
average of 2.5 vs. 1.7 lesions per patient, respectively) that
ere similarly distributed in the proximal 4 cm of the
oronary arteries (49). Similar findings were reported using
ptical coherence tomography, which also revealed other
igns of plaque instability (Fig. 5) (50). Additionally, 1 study
ombined coronary IVUS and optical coherence tomogra-
hy to demonstrate in vivo the association of positive plaque
emodeling with 3 features of vulnerability: a lipid-rich core,
thin fibrous cap, and high macrophage density (51).
oninvasive imaging. The powerful prognostic implica-
ions of coronary calcification in different ethnic groups. (32).ere confirmed in 6,722 asymptomatic participants under-
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Year in Atherothrombosis April 14, 2009:1326–37oing computed tomography (CT) in MESA (Multi-
thnic Study of Atherosclerosis). After adjustment for
onventional risk factors, the likelihood of coronary events
uring a median follow-up of 3.4 years was almost 10 times
igher in subjects with an Agatston calcium score 300 in
omparison with those with absent calcification (Fig. 6)
52). Data from MESA also indicated that the coronary
alcium score is a stronger predictor of events than the
IMT. The adjusted hazard ratios of incident CHD for
ach increment in 1 standard deviation of maximum CIMT
r log-transformed calcium score were 1.2 and 2.5, respec-
ively (53). The role of quantifying coronary calcium in
iabetes was prospectively addressed in an investigation of
89 patients with type 2 diabetes in whom the calcium score
dded prognostic information beyond conventional risk
tratification and multiple serum markers (54).
Another application intensively explored during 2008 was
he evaluation of noncalcified coronary atherosclerosis with
T angiography. A study in 295 symptomatic patients
dentified proximal coronary plaque (noncalcified in one-
hird of the cases) in 44% and 75% of low- and
ntermediate-Framingham risk patients, respectively, many
ithout current indication for statin therapy (55). The
otential prognostic value of CT angiography was high-
ighted in series of 2,538 consecutive patients followed for
Figure 5 Optical Coherence
Tomography of Vulnerable Plaques
Optical coherence tomography images of vulnerable/unstable plaques. (A) Lipid-
rich plaque (L) covered by a thin fibrous cap (arrowheads). (B) Magnification of
the thin fibrous cap (arrows) and lipid core (L). (C) Example of plaque rupture
as a cavity communicating with the lumen, with an overlying fibrous cap frag-
ment (arrows). (D) Example of an irregular thrombus protruding into the lu-
men (arrowheads). Modified, with permission, from Fujii et al. (50).n average of 6.5 years. Triple-vessel nonobstructive coro-ary atherosclerosis was independently associated with mor-
ality and, interestingly, the calcium score still provided
dditive value to the semi-quantitative information derived
rom the CT angiography (56). On the other hand, the use
f CT angiography as a screening modality in asymptomatic
ndividuals seems unjustified based on another study includ-
ng 1,000 individuals (57).
Moving outside of the coronary circulation, an MRI
tudy of the carotid circulation demonstrated complex
laques (those with hemorrhage/thrombosis, cap disrup-
ion, or calcified nodules) in 16% of patients with 50%
uminal stenosis and in 37% of patients with moderate
arrowing, suggesting that high-risk lesions may be identi-
able even in the absence of severe stenosis (58). Using
ltrasound, the degree of post-contrast enhancement in
uman carotid plaques was shown to correlate with the
ensity of neovessels as well as with plaque echolucency,
oth markers of vulnerability (59). Similar correlations were
escribed after the use of contrast-enhanced MRI in an
xperimental model of aortic atherosclerosis that addition-
lly provided in vivo evidence of the association between
nflammation (as quantified with 18fluorodeoxyglucose
ositron emission tomography [PET]) and neovasculariza-
ion (Fig. 7) (60).
olecular imaging. The field of molecular imaging was
articularly active in 2008. In a murine model, MRI and
ron-oxide particles conjugated to an antibody with high
pecificity for platelet integrin GPIIb/IIIa were used to mon-
tor clot formation and lysis (61). Another contrast agent
ontaining a gadolinium chelate and a matrix metallopro-
einase inhibitor successfully identified metalloproteinase-
ich plaques in experimental atherosclerosis (62). Although
onventional MRI relies on the detection of hydrogen
rotons, alternative nuclei can generate MRI-detectable
ignal. Mice with experimental MI were administered 19F
normally absent in the body) in the form of perfluorocar-
Figure 6 Association Between
Coronary Calcification and Events
Unadjusted survival curves for incident coronary events according to the coro-
nary calcium score in the MESA (Multi-Ethnic Study of Atherosclerosis) study.
Reprinted, with permission, from Detrano et al. (52).
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April 14, 2009:1326–37 Year in Atherothrombosison nanoparticles that are phagocytized by macrophages.
his approach enabled assessment of infarct inflammatory
ctivity with impressive contrast-to-noise ratios (63). Sim-
larly, monocyte recruitment into murine aortic plaques could
e monitored for up to 10 days using serial micro single photon
mission computed tomography (SPECT)/CT imaging after
dministration of exogenous 111In-labeled monocytes (64).
9mTc-labeled annexin A5 imaged with SPECT/CT al-
owed for in vivo evaluation of the efficacy of novel caspase
nhibitors as therapeutic agents to reduce foam cell apopto-
is (65). Moving into humans, 18fluorodeoxyglucose PET
as used to quantify inflammatory activity in peripheral
therosclerosis (Fig. 8) (66).
In addition, novel contrast agents designed for multimo-
ality imaging were developed. A study in mice demon-
trated that atherosclerotic lesions could be visualized with
RI using autofluorescent gadolinium-loaded micelles spe-
ific to oxidized LDL, which colocalized with plaque
acrophages on confocal fluorescence microscopy (67).
nother investigation reported the feasibility of detecting
Figure 7 Multimodality Imaging of Plaque Neovascularization a
Multimodality imaging of plaque neovascularization and inflammation in experimen
signal intensity versus time curve with magnetic resonance imaging after contrast
(B) Histology section demonstrating CD31 staining for neovessels (arrow). (C) Po
nal aorta, with higher localized uptake (red markers). Reprinted, with permission,acrophage-rich lesions with an iron-based magnetofluo- oescent nanoparticle additionally labeled with 64Cu, suitable
or imaging with PET, MRI, and optical techniques (68).
revention and Treatment
he importance of primary and secondary cardiovascular
revention was reinforced in 2008. Even modest advances in
isk factor control were associated with large reductions in
isease incidence in a 25-year follow-up (69). Simulation
odels from the National Health and Nutrition Examina-
ion Survey estimated that MIs and strokes in the U.S.
ould be respectively reduced by 63% and 31%, respectively,
ver the next 30 years if all currently recommended preven-
ive measures were implemented, although a staggering 78%
f adults would require at least 1 intervention (70). Even
urther reductions were foreseen if such efforts extended to
ounger individuals (71). Highlighting the influence of
ifestyle choices on risk, the INTERHEART study revealed
hat a diet rich in vegetables and fruit was associated with a
eduction in MI probability of up to 34% (72). The relevance
flammation
erosclerosis in rabbits. (A) Color-coded map derived from the area under the
istration. The cross section of the aorta (arrow) is magnified in the vignette.
emission tomographic image of 18fluorodeoxyglucose uptake along the abdomi-
alcagno et al. (60).nd In
tal ath
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Year in Atherothrombosis April 14, 2009:1326–37HD was also highlighted by the COURAGE (Clinical
utcomes Utilizing Revascularization and Aggressive Drug
valuation) trial: the addition of percutaneous intervention to
ptimized medical therapy modestly improved quality of life
uring the first 1 to 2 years, but these differences were lost by
he third year (73). Moreover, a multidrug regimen of a statin,
spirin, and 2 blood pressure medications for high-risk indi-
iduals in low- and middle-income countries was projected to
revent approximately 20% of cardiovascular deaths over the
ext 10 years (74).
Alternative approaches for improved prevention were
ested in 2008. Encouraging results were reported from
UROACTION, a multinational trial conducted in
ospitals and general practices and that randomized more
han 5,000 patients with established CHD or high risk to
ultidisciplinary intervention or usual care. The multi-
isciplinary intervention program resulted in healthier
ifestyle choices and significant improvements in risk
actor control after 1 year (75). A similar approach led
ot only to superior secondary prevention implementa-
ion but also to modest decreases in 3-year event rates in
ost-MI survivors (76). The importance of population-
argeted preventive measures was highlighted in a report
hat demonstrated significant reductions in the incidence
f acute coronary syndromes after legislation banning
ndoor smoking (77).
ipid therapy. Intensive statin therapy with rosuvastatin
0 mg/day for 2 years was previously shown to cause
oronary plaque regression. A secondary analysis demon-
trated concomitant reductions in luminal stenosis (average
hange: 1.3%) and minimal diameter (average change:
0.03 mm) by quantitative coronary angiography in seg-
ents with25% stenosis at baseline (78). A post hoc analysis
f statin-naïve patients enrolled in the PROVE IT–TIMI 22
Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Figure 8 PET-CT Imaging of Peripheral Arterial Inflammation
(Left) Coronal CT image; (middle) PET image; (right) fused PET-CT image. There is
arteries (arrows). CT  computed tomography; L  left; PET  positron emissionhrombolysis In Myocardial Infarction 22) trial suggested that vhe benefit of intensive statin therapy is larger with higher
evels of baseline LDL and is lost for patients with LDL
evels 66 mg/dl (79). Two additional publications pro-
ided indirect support for a more widespread use of statins
n high-risk subgroups: patients with diabetes (80) and
atients with chronic kidney disease (81).
One of the highlights of the year was the publication of
he JUPITER (Justification for the Use of statins in Primary
revention: an Intervention Trial Evaluating Rosuvastatin)
rial (82). JUPITER randomized 17,802 apparently healthy
50-year-old men and 60-year-old women with LDL
holesterol 130 mg/dl (median: 108 mg/dl) and CRP
evels 2 mg/l (median: 4.3 mg/l) to rosuvastatin 20
g/day or placebo. The trial was stopped prematurely after
median follow-up of 1.9 years because of large and highly
ignificant reductions in both the primary and secondary
nd points in the rosuvastatin group (Table 1). Therapy
ith rosuvastatin reduced LDL concentrations by 50% and
RP levels by 37%; which of these is mainly responsible for
he observed benefits remains a question.
Ezetimibe (10 mg/day) was compared with placebo in 720
atients with familial hypercholesterolemia also receiving sim-
astatin 80 mg/day in the ENHANCE (Ezetimibe and
imvastatin in Hypercholesterolemia Enhances Atheroscle-
osis Regression) trial. Combined therapy for 24 months
ignificantly reduced LDL cholesterol levels (141  53
g/dl vs. 193.7 60.3 mg/dl; p 0.01) but did not change
he rate of disease progression as measured by the CIMT,
he primary end point of the trial (83). It will be necessary
o wait for completion of the ongoing IMPROVE-IT
IMProved Reduction of Outcomes: Vytorin Efficacy Interna-
ional Trial) study to evaluate whether ezetimibe modifies
linical outcomes. Regarding HDL-raising drugs, the per-
xisome proliferator activated receptor-alpha agonist beza-
brate was associated with sustained reductions in cardio-
ed 18fluorodeoxyglucose accumulation in both superficial femoral
raphy; R  right. Reprinted, with permission, from Rudd et al. (66).mark
tomogascular risk in patients with established CHD, although
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April 14, 2009:1326–37 Year in Atherothrombosisnly in patients not receiving other lipid-lowering therapies
84). Moreover, it was suggested that the protective effects
f pioglitazone may be mediated by its ability to raise HDL
oncentrations (85).
ntihypertensive therapy. The benefits of treating hyper-
ension even at advanced ages were demonstrated in the
YVET (Hypertension in the Very Elderly Trial). This
ultinational study randomized 3,845 80-year-old pa-
ients with systolic blood pressure 160 mm Hg to placebo
r sustained-release indapamide ( perindopril) to a target
lood pressure of 150/80 mm Hg. In the intention-to-treat
nalysis, the primary end point (incident fatal or nonfatal
troke) was reduced by 30% (p  0.06), and there were
ignificant reductions in death from stroke (39%), death
rom any cause (21%), and heart failure (64%) (86). How-
ver, a prospective cohort of almost 170,000 Chinese
ndividuals indicated that treated and controlled hyperten-
ion still carries a higher cardiovascular risk than normoten-
ive status, emphasizing the importance of primary preven-
ion (87).
herapy for diabetes. Robust evidence on the importance
f aggressive medical management in patients with diabetes
ecame available in 2008. A regimen of intensive glucose
ontrol to a target glycated hemoglobin value 6.5% was
ompared with standard care in 11,140 type 2 diabetic
atients in the randomized ADVANCE (Diabetes and
ascular Disease: Preterax and Diamicron Modified Re-
ease Controlled Evaluation) trial. After a median follow-up
f 5 years, there was a significant 10% reduction in the
ombined outcome of major macrovascular and microvas-
ular complications, although mainly restricted to microvas-
ular events (88). Longer follow-up was available in the
KPDS (United Kingdom Prospective Diabetes Study)
rial, in which patients with newly diagnosed type 2 diabetes
ere randomized to conventional glucose control (diet) or to
ntensive therapy with sulfonilureas and insulin (or, for
verweight patients, metformin). After the conclusion of
he trial, 3,277 patients were followed for up to 10 addi-
ional years. Among different improvements, some only
pparent during the post-trial period, the intensive therapy
rm experienced significant decreases in total mortality and
ncident MI. These reductions were particularly substantial
utcomes in the JUPITER Trial
Table 1 Outcomes in the JUPITER Trial
Rosuvastatin
Primary end point 7
MI 1
Stroke 1
Arterial revascularization or hospitalization for unstable angina 4
MI, stroke, or cardiovascular death 4
Any death 10
he primary end point includes the combination of nonfatal MI, nonfatal stroke, hospitalization for u
hat the rates observed in the 1.9-year median follow-up of the trial are kept constant.
CI  confidence interval; JUPITER  Justification for the Use of statins in Primary prevention: an the metformin group (Fig. 9) (89). A smaller study candomized 160 type 2 diabetic patients with microalbu-
inuria to conventional or intensive medical therapy for an
verage of 7.8 years, with an additional observational
ollow-up of 5.5 years. The intensive approach (which
ncluded stricter metabolic and blood pressure targets,
ehavioral modification, renin-angiotensin blockers, lipid-
owering drugs, and aspirin) halved the risk of overall
ortality (hazard ratio: 0.54; p  0.02) and cardiovascular
vents (hazard ratio: 0.41; p  0.001) (90). Moreover, a
tudy in 499 American Indian individuals with type 2
iabetes suggested that lower targets of systolic blood
ressure and LDL cholesterol (115 mm Hg and 70
g/dl, respectively) may be appropriate for these patients.
he study did not find differences in events in the limited
-year follow-up period, but reported regression of CIMT
n the intensive arm (91). In an additional imaging inves-
igation, pioglitazone was associated with slower progres-
ion of IVUS-based atheroma than was glimepiride (92).
ntiplatelet therapy. Current guidelines recommend the
emporary addition of clopidogrel to aspirin after an acute
oronary syndrome. A retrospective analysis raised concerns
f a potential rebound effect associated with the interruption
f clopidogrel, with subsequent 90-day clustering of death
nd MI both in patients treated medically and in those
eceiving stents (93). Also addressing dual antiplatelet
herapy in secondary prevention, aspirin plus extended-
elease dipyridamole or clopidogrel alone were similarly
fficacious in reducing the risk of recurrent stroke or the
omposite of stroke, MI, or vascular death among 20,332
atients with a previous noncardioembolic ischemic stroke.
owever, the combination therapy resulted in a 15%
ncrease in the risk of major bleeding (94).
In addition, several studies addressed the hypercoagulable
tate associated with diabetes and its influence on anti-
hrombotic therapy. A trial in 2,539 Japanese individuals
ith type 2 diabetes evaluated the use of low-dose aspirin
or cardiovascular primary prevention. After a median
ollow-up of 4.4 years, aspirin did not reduce global athero-
clerotic events, the primary end point of the trial, but
uggested a potential benefit in the risk of fatal coronary or
erebrovascular events (95). A subanalysis of the TRITON–
IMI 38 (Trial to Assess Improvement in Therapeutic Out-
Event Rates, %*
8,901) Placebo (n  8,091) Hazard Ratio (95% CI) p Value
13.6 0.56 (0.46–0.69) 0.001
3.7 0.46 (0.30–0.70) 0.001
3.4 0.52 (0.34–0.79) 0.002
7.7 0.53 (0.40–0.70) 0.001
8.5 0.53 (0.40–0.69) 0.001
12.5 0.80 (0.67–0.97) 0.02
angina, arterial revascularization, or cardiovascular death. *Expressed as 10-year rates, assuming
ention Trial Evaluating Rosuvastatin; MI  myocardial infarction.(n 
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lopidogrel and prasugrel in 3,146 diabetic patients with an
cute coronary syndrome. The prasugrel arm experienced a
Figure 9 Glucose Control in Diabetes and Prognosis
Comparisons between the intensive versus conventional glucose control arms of t
trial with regard to the cumulative incidence of myocardial infarction (A and B) and
Figure 10 Benefits of Prasugrel in Diabetic Atherothrombosis
Rates of the primary end point (composite of cardiovascular death, nonfatal myoca
in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombol
potent antiaggregation with prasugrel are particularly evident in diabetic patients. D
et al. (96).ignificant 14% reduction in the primary efficacy end point
Fig. 10) without the increased rates of bleeding found in
ondiabetic subjects (96). Moreover, a post hoc analysis of
PDS (United Kingdom Prospective Diabetes Study)
lity (C and D). Modified, with permission, from Holman et al. (89).
nfarction, or nonfatal stroke) in the TRITON-TIMI 38 (Trial to Assess Improvement
Myocardial Infarction 38) trial according to diabetic status. The benefits of more
diabetes mellitus; HR  hazard ratio. Modified, with permission, from Wiviotthe UK
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educed not only first but also subsequent events during
ollow-up (97).
ther therapies. Additional data on the benefits associated
ith blocking the renin-angiotensin system in high-risk
atients came from the ONTARGET (Ongoing Telmisar-
an Alone and in Combination with Ramipril Global
ndpoint Trial) study, which randomized patients with
stablished cardiovascular disease or diabetes with end-
rgan damage to ramipril, telmisartan, or the combination.
fter a median follow-up of almost 5 years, the combination
f cardiovascular death, MI, stroke, or hospitalization for
eart failure occurred in 16.5%, 16.7%, and 16.3% of each
rm, respectively. It was concluded that telmisartan was as
fficacious as ramipril for prevention of events; the combi-
ation did not provide additional benefits despite a greater
eduction in blood pressure (98).
Darapladib, a novel oral lipoprotein-associated phospho-
ipase A2 inhibitor, was compared with placebo in a study of
30 CHD patients who underwent coronary IVUS at
aseline and at 12 months. The change in atheroma volume
as similar between groups, but darapladib was associated
ith no change in necrotic core size whereas the placebo
rm experienced an increase (0.5  13.9 mm3 vs. 4.5 
7.9 mm3; p  0.01) (99). Succinobucol, a novel antioxi-
ant drug, was compared with placebo in patients with
revious acute coronary syndrome. Succinobucol did not
ffect the 2-year rate of the primary end point although it
educed the incidence of the combination of cardiovascular
eath, cardiac arrest, MI, or stroke (100). Finally, another
VUS investigation evaluated the effect on coronary plaque
urden of rimonobant, which caused reductions in total but
ot percent atheroma volume after 18 months of therapy
101).
onclusions
he year 2008 brought numerous advances in our under-
tanding of atherothrombosis. The use of imaging modali-
ies, the importance of intensive medical therapy and risk
actor control (especially in diabetic patients), and novel
ndications for statin therapy constituted the highlights of a
roductive year.
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